| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-09-01 | Intellia Therapeutics (USA - MA) | $70 Million | series B financing round | OrbiMed (USA - NY) Fidelity Biosciences (USA - MA) Management and Research Company (USA - CA) Janus Capital Management (USA - CO) Foresite Capital (USA - NY) Sectoral Asset Management (Canada) EcoR1 Capital (USA - CA) Atlas Venture (USA - MA) Novartis (Switzerland) | Series B financing round | |
| 2015-08-25 | Reneuron (UK) | £68.4 million (€ 93 million) | private placement | new and existing investors including Woodford Investment Management (UK) | Regenerative Medicine | Private placement |
| 2015-08-24 | TRUST project ( Txcell (France) Provepep (France) University Hospital La Pitié Salpêtrière (France) Quinze-Vingts Hospital Center of ophthalmology (France) | € 1.28 million | grant | FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France) | Autoimmune diseases - Inflammatory diseases - Ophtalmological diseases | Grant |
| 2015-08-22 | Helix (USA - CA) | $ 100 million | financing round | Illumina (USA - CA) Warburg Pincus (USA - CA) Sutter Hill Ventures (USA - CA) Mayo Clinic (USA - MN) | Technology - Services | Financing round |
| 2015-08-19 | Telesta Therapeutics (Canada) | $28.6 million | private placement | Consonance Capital Investors (USA - NY) Boxer Capital of Tavistock Life Sciences (Bahamas) Omega Funds (USA - MA) members of the senior management team and board of directors of Telesta | Cancer - Oncology | Private placement |
| 2015-08-19 | Orbus Therapeutics (USA - CA) | $32.5 million | series A financing round | Longitude Capital, H.I.G. BioVentures Adams Street Partners. Dr. Ernest Mario | Series A financing round | |
| 2015-08-19 | Orbus Therapeutics (USA - CA) | $32.5 million | series A financing round | Longitude Capital (USA - CA) H.I.G. BioVentures (USA) Adams Street Partners (USA) Dr. Ernest Mario | Cancer - Oncology - Rare diseases | Series A financing round |
| 2015-08-18 | Medicinova (USA - CA) | private placement | Private placement | |||
| 2015-08-12 | Checkmate Pharmaceuticals (USA - MA) | $ 20 million | series A financing round | Sofinnova Ventures (USA - CA) venBio (USA - CA) | Cancer - Oncology | Series A financing round |
| 2015-08-07 | Santhera Pharmaceuticals (Switzerland) | CHF 27.7 Million (€ 25.8 million) | private placement | Rare diseases - Genetic diseases - Neuromuscular diseases - Ophtalmological diseases | Private placement | |
| 2015-08-05 | Amag Pharmaceuticals (USA - MA) | $231 Million (€ 212.1 million) | private placement | Private placement | ||
| 2015-08-04 | Biophytis (France) | €6 million | capital increase | undisclosed US investor | Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases | Capital increase |
| 2015-07-31 | Kiadis Pharma (The Netherlands) | € 34.7 million | IPO | Cancer - Oncology | IPO | |
| 2015-07-29 | Mereo BioPharma (UK) | $118 million (£76.5 million - € 106.6 million) | series A financing round | Woodford Investment Management (UK) Invesco Perpetual (UK) Novartis (Switzerland) | Rare diseases | Series A financing round |
| 2015-07-28 | Pieris (Germany) | $28.3 million | IPO | IPO | ||
| 2015-07-28 | Erytech Pharma | IPO | Cancer - Oncology - Rare diseases | IPO | ||
| 2015-07-24 | Poxel (France) | € 20 million | capital increase | Metabolic diseases | Capital increase | |
| 2015-07-23 | Exelixis (USA - CA) | $135 million | private placement | Cancer - Oncology | Private placement | |
| 2015-07-22 | KalVista Pharmaceuticals (UK) | $33 million | series B financing round | Novo A/S (Denmark) RA Capital Management (USA - MA) SV Life Sciences (UK - USA) Longwood Fund (USA) Venrock (USA - CA) | Series B financing round | |
| 2015-07-22 | Txcell (France) | € 8 million | private placement | Autoimmune diseases – Inflammatory diseases - Digestive diseases - Ophtalmological diseases | Private placement |
